BR0109846A - Uso de uma composição que compreende um anticorpo ou um fragmento de ligação de antìgeno deste, e conjunto - Google Patents

Uso de uma composição que compreende um anticorpo ou um fragmento de ligação de antìgeno deste, e conjunto

Info

Publication number
BR0109846A
BR0109846A BR0109846-2A BR0109846A BR0109846A BR 0109846 A BR0109846 A BR 0109846A BR 0109846 A BR0109846 A BR 0109846A BR 0109846 A BR0109846 A BR 0109846A
Authority
BR
Brazil
Prior art keywords
antibody
composition
antigen binding
binding fragment
preparations
Prior art date
Application number
BR0109846-2A
Other languages
English (en)
Portuguese (pt)
Inventor
James Peter Burnie
Original Assignee
Neutec Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutec Pharma Plc filed Critical Neutec Pharma Plc
Publication of BR0109846A publication Critical patent/BR0109846A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10Sulfides; Sulfoxides; Sulfones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39575Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR0109846-2A 2000-04-06 2001-03-20 Uso de uma composição que compreende um anticorpo ou um fragmento de ligação de antìgeno deste, e conjunto BR0109846A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0008305.5A GB0008305D0 (en) 2000-04-06 2000-04-06 Treatment of fungal infections
PCT/GB2001/001195 WO2001076627A1 (en) 2000-04-06 2001-03-20 Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies

Publications (1)

Publication Number Publication Date
BR0109846A true BR0109846A (pt) 2003-06-03

Family

ID=9889204

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0109846-2A BR0109846A (pt) 2000-04-06 2001-03-20 Uso de uma composição que compreende um anticorpo ou um fragmento de ligação de antìgeno deste, e conjunto

Country Status (19)

Country Link
US (4) US20030180285A1 (enExample)
EP (4) EP1852128A1 (enExample)
JP (1) JP2003530357A (enExample)
CN (3) CN101683525A (enExample)
AT (1) ATE364396T1 (enExample)
AU (2) AU2001240890B2 (enExample)
BR (1) BR0109846A (enExample)
CA (1) CA2401836A1 (enExample)
CY (1) CY1106794T1 (enExample)
DE (1) DE60128893T2 (enExample)
DK (1) DK1267925T3 (enExample)
ES (1) ES2287105T3 (enExample)
GB (1) GB0008305D0 (enExample)
NO (1) NO20024815L (enExample)
NZ (1) NZ520899A (enExample)
PL (1) PL358394A1 (enExample)
PT (1) PT1267925E (enExample)
RU (1) RU2262952C2 (enExample)
WO (1) WO2001076627A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050129665A1 (en) * 2002-07-25 2005-06-16 Martin Friedlander Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
US7651689B2 (en) * 2002-11-15 2010-01-26 Albert Einstein College Of Medicine Of Yeshiva University Methods of applying ionization radiation for therapy of infections
EP1457499A1 (en) * 2003-03-12 2004-09-15 Tufts University School Of Medicine Inhibitors of extracellular Hsp90
US7959915B2 (en) 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
GB0409077D0 (en) 2004-04-23 2004-05-26 Neutec Pharma Plc Treatment of fungal infections
SG153877A1 (en) * 2004-07-02 2009-07-29 Neutec Pharma Plc Treatment of cancer
CN101010100A (zh) 2004-07-02 2007-08-01 纽泰克医药有限公司 癌症的治疗方法
EP1858542A4 (en) * 2005-02-24 2009-08-19 Joslin Diabetes Center Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VASPEREPERMABILITY
PT2332909E (pt) * 2005-04-13 2014-12-17 Astex Therapeutics Ltd Derivados de hidroxibenzamida e sua utilização como inibidores de hsp90
GB0600168D0 (en) * 2006-01-05 2006-02-15 Neutec Pharma Plc A therapeutic composition
GB0620259D0 (en) * 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
US20100119512A1 (en) * 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
US20100111943A1 (en) * 2007-03-22 2010-05-06 Medical College Of Georgia Research Institute, Inc Compositions and methods for inhibiting cancer metastasis
US20100113355A1 (en) * 2007-04-27 2010-05-06 Naresh Chennamsetty Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
WO2008132174A1 (en) * 2007-04-27 2008-11-06 Novartis Ag An immunoglobulin composition
US10457726B2 (en) 2016-06-30 2019-10-29 University Of Connecticut Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
CN111116743B (zh) * 2018-10-30 2022-01-28 迈威(上海)生物科技股份有限公司 Hsp90抗体及其在抗真菌感染中的应用
CN111679069A (zh) * 2019-12-31 2020-09-18 安徽中医药大学 一种通过耳道念珠菌细胞壁重构来评价中药单体抗真菌作用的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8915019D0 (en) * 1989-06-30 1989-08-23 Matthews Ruth C Medicaments
GB2270076A (en) * 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
US6365165B1 (en) * 1995-09-22 2002-04-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US5834592A (en) * 1995-09-22 1998-11-10 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US6375955B1 (en) * 1995-09-22 2002-04-23 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides

Also Published As

Publication number Publication date
ES2287105T3 (es) 2007-12-16
AU2001240890B2 (en) 2005-06-16
AU4089001A (en) 2001-10-23
US20080181884A1 (en) 2008-07-31
US20030180285A1 (en) 2003-09-25
EP1267925A1 (en) 2003-01-02
NO20024815L (no) 2002-12-02
CN101683525A (zh) 2010-03-31
ATE364396T1 (de) 2007-07-15
US20080193459A1 (en) 2008-08-14
DE60128893D1 (de) 2007-07-26
US20100285029A1 (en) 2010-11-11
NZ520899A (en) 2005-03-24
PT1267925E (pt) 2007-09-04
WO2001076627A8 (en) 2001-11-15
DE60128893T2 (de) 2007-12-06
WO2001076627A1 (en) 2001-10-18
EP2011512A1 (en) 2009-01-07
PL358394A1 (en) 2004-08-09
CA2401836A1 (en) 2001-10-18
NO20024815D0 (no) 2002-10-04
EP1267925B1 (en) 2007-06-13
EP1267925B8 (en) 2007-08-29
EP1852128A1 (en) 2007-11-07
EP1818062A1 (en) 2007-08-15
EP1818062A3 (en) 2007-10-24
CN1420786A (zh) 2003-05-28
JP2003530357A (ja) 2003-10-14
CN101095952A (zh) 2008-01-02
CY1106794T1 (el) 2012-05-23
RU2002129510A (ru) 2004-03-27
RU2262952C2 (ru) 2005-10-27
DK1267925T3 (da) 2007-10-15
GB0008305D0 (en) 2000-05-24

Similar Documents

Publication Publication Date Title
BR0109846A (pt) Uso de uma composição que compreende um anticorpo ou um fragmento de ligação de antìgeno deste, e conjunto
TR200001218T2 (tr) İkameli karboksamidotiazoller, bunların üretimi ve bunları içeren farmasötik bileşimler.
FR14C0064I2 (fr) Anticorps anti-il-6, compositions, methodes et utilisations associees
EP1071460A4 (en) INTERNALIZING ERB2 ANTIBODIES
BR0315275A (pt) Anticorpos que se ligam a receptor de eritropoietina
BR0305074A (pt) Composições cosméticas com alta afinidade
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
BR9812634A (pt) April - uma proteìna com efeitos de crescimento
MA30474B1 (fr) Formulations de molecule peptide(s) -anticorps therapeutique lyophilisee.
HUS1600019I1 (hu) Polipeptideket tartalmazó készítmények
ATE293159T1 (de) Stabilisierendes verdünnungsmittel für polypeptide und antigene
DK1144472T3 (da) Vandige reaktive spartelmasser (II)
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
SE0102327D0 (sv) A novel engineered superantigen for human therapy
DE69840603D1 (de) Alpha-ketoamidhaltige multikatalytische protease inhibitoren
BR0316324A (pt) Polipeptìdeos e conjugados de interferon-alfa
ATE330017T1 (de) Kallikrein gen
WO2003048207A3 (en) Anti-dota antibody
TR200100455T2 (tr) Nimesulid içeren topikal farmasötik bileşimler
CY1105009T1 (el) Συνθεση καχαλαλιδης f
SE0003538D0 (sv) New immunogenic complex
ATE323763T1 (de) Dna & protein bindende miniatur proteine
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
DK1279677T3 (da) GD3-mimetiske peptider
BRPI0208124B8 (pt) uso de um anticorpo igy imunologicamente específico para a proteína paa associada à virulência de escherichia coli de ligação e eliminação (aeec)

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NEUTEC PHARMA LTD. (GB)

Free format text: ALTERADO DE: NEUTEC PHARMA PLC

B25G Requested change of headquarter approved

Owner name: NEUTEC PHARMA LTD. (GB)

Free format text: SEDES ALTERADAS CONFORME SOLICITADO NA PETICAO NO 020080104515/RJ DE 30/07/2008.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2206 DE 16/04/2013.